Publication Name	World Journal of Hepatology
Manuscript ID	33223
Country	United Kingdom

Received	2017-02-07 18:42
Peer-Review Started	2017-02-13 14:37
To Make the First Decision	2017-03-08 09:41
Return for Revision	2017-03-10 17:22
Revised	2017-04-26 04:48
Second Decision	2017-05-07 16:02
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2017-05-15 05:47
Articles in Press	2017-05-15 05:47
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-06-02 07:41
Publish the Manuscript Online	2017-06-20 12:50

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Systemic treatment of hepatocellular carcinoma: Past, present and future
Manuscript Source	Invited Manuscript
All Author List	Esther Una Cidon
Funding Agency and Grant Number
Corresponding Author	Esther Una Cidon, MD, PhD, Medical Oncologist, Department of Medical Oncology, Royal Bournemouth Hospital, Castle Lane East, Castle Ln E, BH7 7DW Bournemouth, United Kingdom. esther.unacidon@rbch.nhs.uk
Key Words	Hepatocellular carcinoma; Alphafetoprotein; Sorafenib; Nivolumab; MEK
Core Tip	The incidence of hepatocellular carcinoma (HCC) is rising in Western countries due to hepatitis C. Unfortunately, 40% of patients present with advanced disease which is only amenable for palliative systemic treatment. The development of effective therapies for HCC is a challenge, due partly to its inherent chemo­resistance, the pharmacologic challenges due to an ill liver, etc. Although some responses to traditional chemo­therapy have been reported, the multikinase inhibitor sorafenib has shown survival benefit in advanced HCC with preserved liver function. Recently immunotherapy seems to be a promising approach for some patients.
Publish Date	2017-06-20 12:50
Citation	Cidon EU. Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol 2017; 9(18): 797-807
URL	http://www.wjgnet.com/1948-5182/full/v9/i18/797.htm
DOI	http://dx.doi.org/10.4254/wjh.v9.i18.797

Full Article (PDF)	WJH-9-797.pdf
Full Article (Word)	WJH-9-797.doc
Manuscript File	33223-Review.docx
Answering Reviewers	33223-Answering reviewers.pdf
Audio Core Tip	33223-Audio core tip.aiff
Conflict-of-Interest Disclosure Form	33223-Conflict-of-interest statement.pdf
Copyright License Agreement	33223-Copyright assignment.pdf
Peer-review Report	33223-Peer-review(s).pdf
Scientific Misconduct Check	33223-Scientific misconduct check.pdf
Scientific Editor Work List	33223-Scientific editor work list.pdf